Lead Plaintiff Deadline is Approaching - Act Now

Regeneron Pharmaceuticals Inc.® Class Action

Radtke v. Regeneron Pharmaceuticals, Inc. et al.

Regeneron Pharmaceuticals Inc

NASDAQ: REGN

Class Period : 11/02/2023 - 10/30/2024

Lead Plaintiff Motion Deadline: 3/10/2025

Alleged Misstatements and Omissions
The Regeneron® class action lawsuit alleges that the company misled investors by making false and misleading statements and concealing critical details about its business practices. Key allegations include:

  • Unreported Price Concessions: Regeneron paid credit card fees for distributors because they did not charge higher prices to customers using credit cards to purchase Eylea.
  • Misleading Sales Reports: These payments were not reported as price concessions, which inflated Eylea's Average Sales Price (ASP) submitted to federal agencies, violating the False Claims Act.
  • Boosted Competitive Advantage: The subsidized fees deceptively boosted Eylea’s reported sales and misrepresented the company's financial performance.

These omissions gave an inaccurate view of Regeneron’s operations, sales practices, and regulatory compliance.

Effects on Stock Prices
The truth began to emerge through two significant developments:

  1. DOJ Complaint: On April 10, 2024, the U.S. Department of Justice (DOJ) announced a False Claims Act complaint against Regeneron, alleging it failed to disclose millions in discounts provided to distributors via reimbursed credit card fees.
    • Stock Price Impact: Following this news, Regeneron’s stock declined by $31.50, or 3.4%, over two trading days, closing at $904.70 on April 12, 2024.
  2. Disappointing Financial Results: On October 31, 2024, Regeneron reported lackluster third-quarter 2024 sales, with U.S. Eylea HD sales of $392 million—well below consensus estimates of $415–$425 million—and a lower net selling price compared to the previous year.
    • Stock Price Impact: The stock fell $84.59, or 9.2%, closing at $838.20 on the same day.

These developments revealed the adverse financial and regulatory impacts previously concealed by the company.

Legal Rights for Affected Shareholders
Shareholders who purchased Regeneron stock prior to April 10, 2024, may have legal grounds to recover their losses. The lawsuit alleges violations of securities laws and misrepresentations regarding Eylea’s sales and pricing practices.

By participating in the class action, affected shareholders can:

  • Seek compensation for financial losses tied to Regeneron stock.
  • Hold the company accountable for its alleged misstatements and omissions.
  • Advocate for greater transparency in corporate reporting and practices.

You may qualify to join the lawsuit if you purchased Regeneron shares and suffered financial harm.

Take Action Today
Protect your rights by taking the first step today. Contact experienced legal professionals specializing in securities fraud cases to explore your options and ensure your claim is filed before legal deadlines.

Join the Regeneron class action to align with other affected investors and demand accountability and fair compensation. Time is critical—act now to safeguard your legal rights.

iStock-2041838047

At DiCello Levitt, we defend the rights of shareholders harmed by deceptive corporate practices. Our experienced legal team will tirelessly hold Regeneron Pharmaceuticals, Inc.® accountable and seek fair compensation for your losses.  

Here's how we can help:  

  1. Conduct a thorough investigation into your claim.  
  2. Build a strong case to hold the company accountable for its misleading actions.  
  3. Fight for maximum compensation on your behalf.  

Contact DiCello Levitt today for a free, private case evaluation. We will assess your potential compensation value and guide you through every step of the process. Take the first step toward justice and reclaim your financial losses now.

All victims affected by Regeneron Pharmaceuticals, Inc.® alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

Find Out if You may be a Member
of the Class

Regeneron Pharmaceuticals Inc.® Class Action

Radtke v. Regeneron Pharmaceuticals, Inc. et al.

Regeneron Pharmaceuticals Inc

NASDAQ: REGN

Class Period : 11/02/2023 - 10/30/2024

Lead Plaintiff Motion Deadline: 3/10/2025

Alleged Misstatements and Omissions
The Regeneron® class action lawsuit alleges that the company misled investors by making false and misleading statements and concealing critical details about its business practices. Key allegations include:

  • Unreported Price Concessions: Regeneron paid credit card fees for distributors because they did not charge higher prices to customers using credit cards to purchase Eylea.
  • Misleading Sales Reports: These payments were not reported as price concessions, which inflated Eylea's Average Sales Price (ASP) submitted to federal agencies, violating the False Claims Act.
  • Boosted Competitive Advantage: The subsidized fees deceptively boosted Eylea’s reported sales and misrepresented the company's financial performance.

These omissions gave an inaccurate view of Regeneron’s operations, sales practices, and regulatory compliance.

Effects on Stock Prices
The truth began to emerge through two significant developments:

  1. DOJ Complaint: On April 10, 2024, the U.S. Department of Justice (DOJ) announced a False Claims Act complaint against Regeneron, alleging it failed to disclose millions in discounts provided to distributors via reimbursed credit card fees.
    • Stock Price Impact: Following this news, Regeneron’s stock declined by $31.50, or 3.4%, over two trading days, closing at $904.70 on April 12, 2024.
  2. Disappointing Financial Results: On October 31, 2024, Regeneron reported lackluster third-quarter 2024 sales, with U.S. Eylea HD sales of $392 million—well below consensus estimates of $415–$425 million—and a lower net selling price compared to the previous year.
    • Stock Price Impact: The stock fell $84.59, or 9.2%, closing at $838.20 on the same day.

These developments revealed the adverse financial and regulatory impacts previously concealed by the company.

Legal Rights for Affected Shareholders
Shareholders who purchased Regeneron stock prior to April 10, 2024, may have legal grounds to recover their losses. The lawsuit alleges violations of securities laws and misrepresentations regarding Eylea’s sales and pricing practices.

By participating in the class action, affected shareholders can:

  • Seek compensation for financial losses tied to Regeneron stock.
  • Hold the company accountable for its alleged misstatements and omissions.
  • Advocate for greater transparency in corporate reporting and practices.

You may qualify to join the lawsuit if you purchased Regeneron shares and suffered financial harm.

Take Action Today
Protect your rights by taking the first step today. Contact experienced legal professionals specializing in securities fraud cases to explore your options and ensure your claim is filed before legal deadlines.

Join the Regeneron class action to align with other affected investors and demand accountability and fair compensation. Time is critical—act now to safeguard your legal rights.

iStock-2041838047

At DiCello Levitt, we defend the rights of shareholders harmed by deceptive corporate practices. Our experienced legal team will tirelessly hold Regeneron Pharmaceuticals, Inc.® accountable and seek fair compensation for your losses.  

Here's how we can help:  

  1. Conduct a thorough investigation into your claim.  
  2. Build a strong case to hold the company accountable for its misleading actions.  
  3. Fight for maximum compensation on your behalf.  

Contact DiCello Levitt today for a free, private case evaluation. We will assess your potential compensation value and guide you through every step of the process. Take the first step toward justice and reclaim your financial losses now.

All victims affected by Regeneron Pharmaceuticals, Inc.® alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

100% Free & Secure Case Evaluations

Answer a few basic questions to get started

We'll ask specific questions to understand the situation, damage risk, and other vital information to help determine the next steps.

Receive a confidential evaluation

A qualified legal team led by a Financial Products Litigation attorney will consider the facts of your case.

Regeneron Pharmaceuticals, Inc.® Investors may have grounds to pursue legal action and financial recovery of damages.

This website offers general information only and is not legal or investment advice. This advertisement is not associated with any government agency.

www.stockfraudclaim.com is the property of Shield Legal LLC. 5170 Badura Ave Las Vegas, NV 89118

Participating law firm: DiCello Levitt LLP, 10 North Dearborn Street Sixth Floor Chicago, IL 60602. For additional terms, disclaimers, and conditions, please visit https://dicellolevitt.com/privacy-policy/

This website is not part of the Facebook website or Facebook, Inc., and it is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of Facebook, Inc.

ATTORNEY ADVERTISING. This Website does not provide investment, legal, or medical advice. Every case is evaluated on its facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Stock Fraud Claim does not itself provide legal services. Cases will be referred to third-party attorneys and law firms.  Court costs and case expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement, or dramatization and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either expressed or implied. Anyone considering a lawyer should independently investigate the lawyer's credentials and ability, and not rely upon advertisements or self-proclaimed expertise. Only persons age 18 or older have permission to access our Service. Our Service does not address anyone under 13 ("Children").

NO ATTORNEY-CLIENT RELATIONSHIP. Use of this website, including sending or receiving information through it, does not establish an attorney-client relationship, nor is any non-passworded information considered privileged or confidential. No class has been certified.  Until a case is filed and a class is certified, you are not represented by counsel unless you retain one.  You may select counsel of your choice.  An attorney-client relationship with DiCello Levitt is established only by an express written agreement signed by DiCello Levitt to represent you.

Attorney Advertising.  Prior results do not guarantee a similar outcome.

Privacy Policy | Terms and Conditions | CCPA Privacy Notice | Do Not Sell My Info

©2024 Stock Fraud Claim. All Rights Reserved